Neurodegenerative Disease Treatment Market, Global Outlook and Forecast 2023-2028

Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
This report contains market size and forecasts of Neurodegenerative Disease Treatment in Global, including the following market information:
Global Neurodegenerative Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Neurodegenerative Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Neurotransmitter Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neurodegenerative Disease Treatment include Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc. and Sanofi and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurodegenerative Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurodegenerative Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Neurodegenerative Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Global Neurodegenerative Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Neurodegenerative Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson's Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy
Huntington's Disease
Global Neurodegenerative Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Neurodegenerative Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurodegenerative Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Neurodegenerative Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.